Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of siRNA of long non-coding RNA SMAD5-AS1 in the treatment of ovarian cancer

A SMAD5-AS1, ovarian cancer technology, applied in the field of bioengineering, can solve problems such as unseen research

Active Publication Date: 2021-05-25
HARBIN MEDICAL UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is worth noting that SMAD5-AS1 was upregulated by 6.7 times in ovarian cancer tissue and 6.0 times in serum, which indicated the potential important role of SMAD5-AS1 in ovarian cancer, and whether SMAD5-AS1 played a role in the disease Its role is still unknown, and whether the inhibition of SMAD5-AS1 gene expression has a therapeutic effect on the disease has not been studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of siRNA of long non-coding RNA SMAD5-AS1 in the treatment of ovarian cancer
  • Application of siRNA of long non-coding RNA SMAD5-AS1 in the treatment of ovarian cancer
  • Application of siRNA of long non-coding RNA SMAD5-AS1 in the treatment of ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 confirms that LncRNA SMAD5-AS1 is upregulated in ovarian cancer

[0026]We used gene chip technology (GeneChip Exon 1.0 ST Arrays from Affymetrix, Inc.) to detect the expression profile of lncRNAs in cancer tissues of ovarian cancer patients (Table 1). The lncRNA chip includes transcripts annotated as lncRNA from RNAdb, Refseq, NCBI Gene, UCSC Gene and other authoritative databases, and the data is comprehensive and reliable. Using bioinformatics analysis methods for data analysis, we selected lncRNAs that were increased or decreased by more than 2 times as differentially expressed genes. Thus, we screened out 1945 lncRNAs that were significantly increased and 1582 differential lncRNAs that were significantly decreased in ovarian cancer patients. The results are shown in the hierarchical clustering diagram ( figure 1 ) and volcano map ( figure 2 ) shown. We also performed pathway analysis related to differential lncRNAs. The results revealed that these ab...

Embodiment 2

[0030] Example 2 confirms that LncRNA SMAD5-AS1 siRNA-1 and siRNA-2 inhibit ovarian cancer cell progression

[0031] We cultured human epithelial ovarian cancer cell line SKOV3 for experiments, and used RPMI1640 medium containing 10% FBS for routine culture at 37°C, 5% CO 2 cultured in a saturated humidity incubator. Grouped as follows: SMAD5-AS1 siRNA-1 (shown in SEQ ID NO.2) transfection group, SMAD5-AS1 siRNA-2 (shown in SEQ ID NO.3) transfection group, siRNA-NC (shown in SEQ ID NO.4) Indicated) transfection group. Real-time fluorescence quantitative PCR was used to detect the expression level of SMAD5-AS1 in each group of cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of siRNA of long non-coding RNA (long non-coding RNA, lncRNA) SMAD5-AS1 in the treatment of ovarian cancer. The present invention designs and synthesizes an siRNA sequence that specifically targets and inhibits SMAD5-AS1, and transfects it into ovarian cancer cell lines. It is confirmed that inhibiting the expression of SMAD5-AS1 can significantly inhibit the proliferation, migration and invasion of ovarian cancer cells. The invention provides a new method and a new drug development direction for the treatment of ovarian cancer.

Description

technical field [0001] The invention relates to the application of siRNA of LncRNA SMAD5-AS1 in the treatment of ovarian cancer, and the invention belongs to the technical field of bioengineering. Background technique [0002] Malignant ovarian tumors are the leading cause of death in patients with gynecological reproductive system malignancies and the fifth leading cause of death from malignant tumors in women (CA Cancer J Clin.2017; 67(1):7-30). According to the latest research data from the United States, there are 225,500 new cases of ovarian cancer diagnosed each year in the world, and the mortality rate is as high as 62%. Although the incidence of ovarian cancer has declined over the past few decades due to changes in hormone replacement therapy, research on the diagnosis and treatment of ovarian cancer has not made significant progress. Epithelial ovarian cancer (Epithelial ovarian cancer, EOC), commonly known as ovarian cancer, accounts for about 90% of ovarian mali...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113A61K31/7105A61P35/00
CPCA61K31/7105C12N15/1135C12N2310/141
Inventor 刘倩肖磊刘辉车德红
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com